Discontinued psychiatric drugs in 2008
- PMID:19715445
- DOI: 10.1517/13543780903184591
Discontinued psychiatric drugs in 2008
Abstract
During the past several decades, neuropsychiatric agents have been one of the fastest growing classes of medicinal agents. This expansion is in part due to the increased recognition of the prevalence and burden of illness associated with disparate neuropsychiatric disorders, increased public awareness and possibly reduced stigma associated with mental illness, as well as extensive marketing of neuropsychiatric agents to healthcare providers. Most of the agents reviewed herein represent modifications and/or refinements of pre-existing agents and/or theoretical approaches (e.g., monoamine hypothesis). There remains a relative paucity of agents with genuinely novel mechanisms targeting effector systems implicated in contemporary models of disease pathophysiology in mood and psychotic disorders (e.g., glutamate, insulin, brain derived neurotrophic factor and other growth factors, immunoinflammatory systems and oxidative stress).
Similar articles
- Glucocorticoid antagonists in neuropsychiatric [corrected] disorders.Schatzberg AF, Lindley S.Schatzberg AF, et al.Eur J Pharmacol. 2008 Apr 7;583(2-3):358-64. doi: 10.1016/j.ejphar.2008.01.001. Epub 2008 Jan 19.Eur J Pharmacol. 2008.PMID:18339372Review.
- A pathophysiological paradigm for the therapy of psychiatric disease.Spedding M, Jay T, Costa e Silva J, Perret L.Spedding M, et al.Nat Rev Drug Discov. 2005 Jun;4(6):467-76. doi: 10.1038/nrd1753.Nat Rev Drug Discov. 2005.PMID:15931256Review.
- [Off-label applications (professional rationales, financial possibilities)].László P.László P.Neuropsychopharmacol Hung. 2007 Oct;9(3):111-2.Neuropsychopharmacol Hung. 2007.PMID:18399028Hungarian.No abstract available.
- Drug treatment of HIV associated neuropsychiatric syndromes.Ayuso Mateos JL, Singh AN, Catalán J.Ayuso Mateos JL, et al.Neurologia. 2000 Apr;15(4):164-71.Neurologia. 2000.PMID:10846884Review.
- Pharmacodynamic and pharmacokinetic interactions of psychotropic drugs with antiepileptic drugs.Kanner AM, Gidal BE.Kanner AM, et al.Int Rev Neurobiol. 2008;83:397-416. doi: 10.1016/S0074-7742(08)00022-6.Int Rev Neurobiol. 2008.PMID:18929094Review.
Cited by
- Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?Griebel G, Holsboer F.Griebel G, et al.Nat Rev Drug Discov. 2012 May 18;11(6):462-78. doi: 10.1038/nrd3702.Nat Rev Drug Discov. 2012.PMID:22596253Review.
- Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function.Dale E, Pehrson AL, Jeyarajah T, Li Y, Leiser SC, Smagin G, Olsen CK, Sanchez C.Dale E, et al.CNS Spectr. 2016 Apr;21(2):143-61. doi: 10.1017/S1092852915000425. Epub 2015 Sep 8.CNS Spectr. 2016.PMID:26346726Free PMC article.Review.
- The vasopressin Avpr1b receptor: molecular and pharmacological studies.Roper J, O'Carroll AM, Young W 3rd, Lolait S.Roper J, et al.Stress. 2011 Jan;14(1):98-115. doi: 10.3109/10253890.2010.512376. Epub 2010 Sep 9.Stress. 2011.PMID:20828336Free PMC article.Review.
- Role of Oxytocin and Vasopressin in Neuropsychiatric Disorders: Therapeutic Potential of Agonists and Antagonists.Cid-Jofré V, Moreno M, Reyes-Parada M, Renard GM.Cid-Jofré V, et al.Int J Mol Sci. 2021 Nov 8;22(21):12077. doi: 10.3390/ijms222112077.Int J Mol Sci. 2021.PMID:34769501Free PMC article.Review.
- Nicotine receptor partial agonists for smoking cessation.Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T.Cahill K, et al.Cochrane Database Syst Rev. 2016 May 9;2016(5):CD006103. doi: 10.1002/14651858.CD006103.pub7.Cochrane Database Syst Rev. 2016.Update in:Cochrane Database Syst Rev. 2023 May 5;5:CD006103. doi: 10.1002/14651858.CD006103.pub8.PMID:27158893Free PMC article.Updated.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous